Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-03-31 | Reverse | 1:40 |
| 2023-08-21 | Reverse | 1:20 |
| 2023-08-17 | Reverse | 1:20 |
| 2015-09-17 | Reverse | 1:10 |
| 2014-01-08 | Reverse | 1:5 |
| 2014-01-03 | Reverse | 1:5 |
Akari Therapeutics, Plc is a London-based clinical-stage biopharmaceutical company developing therapies like nomacopan for autoimmune and inflammatory diseases such as PNH, Guillain-Barré, and thrombotic microangiopathy.
AKTX-101 is a preclinical, next-generation ADC targeting Trop2 on solid tumors, serving as Akari's lead candidate and reflecting its focus on innovative cancer therapies.
Akari Therapeutics announced a pivotal partnership with WuXi XDC to begin GMP manufacturing of its lead antibody-drug conjugate (ADC) candidate, AKTX-101. This was a watershed moment for the company, signaling its transition from a preclinical to a clinical-focused biotechnology player and laying the groundwork for a first-in-human trial planned for late 2026 or early 2027.
Akari initiated a strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing, to produce GMP-grade AKTX-101. This is a critical milestone that enables the company to advance its lead antibody-drug conjugate (ADC) program into first-in-human clinical trials and marks its transition from a preclinical to a clinical-stage oncology company.
Patent filing covers PH1 payload's unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 DRMA | $1.13 | COMPARE |
 REVB | $0.78 | COMPARE |
 CDT | $0.90 | COMPARE |
 PPBT | $1.43 | COMPARE |
 XAGE | $0.12 | COMPARE |
 PBM | $5.49 | COMPARE |
 VINC | $0.01 | COMPARE |
 VRPX | $0.01 | COMPARE |
